project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9LY; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.71; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.77; rna integrity number: 9.1; age at index: 60; days to birth: -21942; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1952; age at diagnosis: 21942; ajcc clinical m: M0; ajcc clinical t: T2b; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 370.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 404; initial weight: 100.0; sample id: 1c2a0f48-b53c-4c9a-bb84-b7455c25e3c8; sample submitter id: TCGA-ZG-A9LY-01A; portion id: b42bdb23-4d24-48ff-bbb2-c71729cc2ae3; portion submitter id: TCGA-ZG-A9LY-01A-11; slide id: c74d39b1-068a-4519-9b39-62c4f4809fb8; slide submitter id: TCGA-ZG-A9LY-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 25.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;